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ABSTRACT
The dramatic acceleration in identification of new
nucleic-acid-based therapeutic molecules has pro-
vided new perspectives in pharmaceutical research.
However, their development is limited by their poor
cellular uptake and inefficient trafficking. Here we
describe a short amphipathic peptide, Pep-3, that
combines a tryptophan/phenylalanine domain with
a lysine/arginine-rich hydrophilic motif. Pep-3 forms
stable nano-size complexes with peptide-nucleic
acid analogues and promotes their efficient delivery
into a wide variety of cell lines, including primary
and suspension lines, without any associated
cytotoxicity. We demonstrate that Pep-3-mediated
delivery of antisense-cyclin B1-charged-PNA blocks
tumour growth in vivo upon intratumoral and
intravenous injection. Moreover, we show that
PEGylation of Pep-3 significantly improves complex
stability in vivo and consequently the efficiency of
antisense cyclin B1 administered intravenously.
Given the biological characteristics of these vec-
tors, we believe that peptide-based delivery tech-
nologies hold a true promise for therapeutic
applications of DNA mimics.
INTRODUCTION
The design of potent systems for the delivery of charged
and non-charged molecules that target genes of interest
remains a major challenge in therapeutics (1–3). Among
antisense DNA mimics, peptide nucleic acids (PNAs) and
their derivatives are very promising tools for antisense
therapy in both eukaryotic and prokaryotic cells, as they
present several advantages including speciﬁc gene target-
ing, high stability, resistance to nucleases and proteases,
and bind RNA and DNA targets in a sequence-speciﬁc
manner with high aﬃnity (4,5). However, as for many
large macromolecules, therapeutic applications of unmo-
diﬁed PNAs remain limited by their low cellular uptake
and poor ability to reach their intracellular target (1,5,6).
Recently, substantial progress has been made in the
development of cell penetrating peptide-based drug
delivery systems that are able to overcome both extra-
cellular and intracellular limitations (7–9). The family of
cell penetrating peptides (CPPs) includes several peptide
sequences: synthetic and natural cell-permeable peptides,
protein transduction domains (PTDs) and membrane-
translocating sequences which have been successfully used
to improve the delivery of covalently linked peptides/
proteins or antisense molecules into cells (7–11). Several
chemical modiﬁcations based on covalently linked cell-
penetrating peptides have been successfully used to
improve PNA and PNA analogue delivery into cultured
cells (5,6,11–14) as well as PNA bioavailability and
activity in vivo (5,15). As an alternative to covalent
PTDs, we have designed a strategy for the delivery of
diﬀerent cargoes into mammalian cells, based on a short
amphipathic peptide carrier that does not require
prior chemical covalent coupling or denaturation steps
(16–18). We have previously proposed a novel technology
that combines a non-covalent peptide-based delivery
system, Pep-2 (19,20) with a negatively charged PNA-
like DNA mimic, HypNA-pPNA, (Figure 1A) consisting
of a phosphonate analogue of a PNA and a PNA-like
monomer based on a trans-4-hydroxyl-L-proline (21).
In the present work, we describe a rational structure-
based design of a new peptide carrier, Pep-3, that forms
stable nano-size complexes with both uncharged
and charged PNAs and promotes their cellular uptake in
diﬀerent cell lines. Moreover, we have elaborated a
Pep-3-based protocol for systemic intravenous or
intratumoral administration of a potential therapeutic
antisense HyPNA-pPNA targeting cyclin B1 into a
xenografted animal tumour model. Pep-3-mediated deliv-
ery is the ﬁrst non-covalent approach described so far that
allows in vivo delivery of DNA mimics. Our study not
only demonstrates the potency of Pep-3 for delivery of
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also constitutes a major improvement over existing
methods.
MATERIALS AND METHODS
Peptide synthesis andanalysis
All peptides were synthesized by solid-phase peptide
synthesis using AEDI-expansin resin with a 9050 Pep
Synthesizer (Millipore, Wartford, UK) according to
Fmoc/tBoc method and puriﬁed as already described
(16,17) on a pioneer peptide synthesizer (Pioneer
TM,
Applied Biosystems, Foster City, CA, USA) starting
from Fmoc-PAL-PEG-PS resin at a 0.2mmol scale.
The coupling reactions were performed with 0.5M of
HATU in the presence of 1M of DIEA. Protecting
group removal and ﬁnal cleavage from the resin
were carried out with TFA/Phenol/H2O/Thioanisol/
Ethanedithiol (82.5/5/5/5/2.5%) for 3h 30min. All
peptides were N-acetylated and bear a cysteamide group
at their carboxy-terminus (-NH-CH2-CH2-SH). The crude
peptide was puriﬁed by RP-HPLC on a C
18 column
(Interchrom UP5 WOD/25M Uptispere 300 5 ODB,
250 21.2mm). Electrospray ionization mass spectra
were in complete agreement with the proposed structure.
Mono-PEGylated-Pep-3 conjugation was performed
at the primary amino group of the N-terminal residues,
using aldehyde monoethoxypoly(ethylene glycol) at
pH 5.5, then PEGylated-peptide was further puriﬁed by
RP-HPLC and analysed by electro spray ionization mass
spectroscopy (16,17).
PNA and HypNA-pPNA synthesis
Classical PNAs were obtained from Applied Biosystems
(Foster city, CA, USA) and HypNA-pPNAs were made
by solid-phase synthesis using a derivatized CPG support
on a DNA synthesizer (Applied Biosystems 380B auto-
mated DNA synthesizer) as previously described and
obtained by Active Motif Inc. (21) sequences correspond
to the 18 mer antisense PNA. Three diﬀerent antisense
sequences were used, targeting respectively the ﬁrst
codons, Cyc-B1a (TGC CAT CGG GCT TGG AGG)
and Cyc-B1c (GCG CTT TGC GCC TGC CAT) and
position 475–492, Cyc-B1b (TCC ATC TTC TGC ATC
CAC) of the open reading frame the cyclin B1 gene.
A sequence derived from Cyc-B1a harbouring two
mismatches, Cyc-B1
mm (TGC CAT CAG GCT TAG
AGG) and an antisense sequence targeting ﬁreﬂy lucifer-
ase (TGG CGT CGG TGA CCA TT) were used as
controls to validate target speciﬁcity.
Proteins andantibodies
Mouse monoclonal anti-cyclin B1 antibodies (SC-245) and
rabbit polyclonal anti-cdk2 antibodies (SC-163) for
western blotting were obtained from Santa Cruz
Biotechnology Inc. (Santa Cruz, CA, USA).
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Figure 1. Evaluation of Pep-2-peptide derivatives. (A) Chemical structure of the DNA mimics; HypNA-pPNA. (B) Binding of peptide carrier to
HypNA-pPNA as monitored by intrinsic ﬂuorescence. Tryptophan ﬂuorescence was excited at 290nm and emission was measured at 340nm. A ﬁxed
concentration of 100nM of peptide Pep-3 (green), Pep-2 (red), Pep-20 (grey), Pep-34 (blue) and Pep-26 (orange), was titrated with increasing
concentrations of HypNA-pPNA. Curves were ﬁtted according to a quadratic equation and dissociation constants estimated to 15 2nM, 37 8nM,
104 12nM, 0.47 0.12mM and 5.2 0.7mM for Pep-3, Pep-2, Pep-20, Pep-34 and Pep-26, respectively. Results correspond to the means of four
separate experiments. Pep-mediated cellular uptake of PNA and HypNA-pPNA. (C) A concentration of 0.5mM of ﬂuorescently labelled HypNA-
pPNA was mixed with Pep-29 (panel 1), Pep-32 (panel 2), Pep-3 (panel 3) at a molar ratio 1/20, incubated for 30min at 378C, then overlaid onto
cultured HeLa cells for 1h, after which cells were extensively washed prior to observation on living cells. Similar experiments were performed with
ﬂuorescently labelled PNA mixed with Pep-3at a molar ratio of 1:20 (panel 4).
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Adherent ﬁbroblastic HeLa, primary human umbilical
vein endothelial cells (HUVEC), Jurkat T, PC3 and
MCF-7 cell lines (from American Type culture collections;
ATCC) were cultured in Dulbecco’s Modiﬁed Eagle’s
Medium supplemented with 2mM glutamine,
1% antibiotics (streptomycin 10000mg/ml, penicillin,
10000IU/ml) and 10% (w/v) foetal calf serum (FCS), at
378C in a humidiﬁed atmosphere containing 5% CO2.
For Peptide- (Pep-2, Pep-3, MPG) mediated delivery of
PNA and HypNA-pPNA, stock solutions of HypNA-
pPNA/peptide and PNA/peptide complexes were formed
by incubation of antisense HypNA-pPNA or PNA with
carrier peptide at a molecular ratio of 1/20 in PBS for
30min at 378C, then were diluted to the required
concentration in 500ml of DMEM. Cells grown to 60%
conﬂuence were then rinsed twice and overlaid with
preformed complexes. After a 30-min incubation at
378C, 1ml of fresh DMEM supplemented with
10% foetal calf serum was added directly to the cells,
without removing the overlay of PNA/peptide or HypNA-
pPNA/peptide complexes, and cells were returned to the
incubator for 24h. For suspension cell lines, cells were
harvested by centrifugation and resuspended directly
with the preformed complex solutions for 5min and
then the level of foetal calf serum was adjusted to 10%.
Lipid-based delivery of HypNA-pPNA, transfections were
performed with Lipofectamine 2000 (Invitrogen,
Carlsbad, CA, USA), according to the protocols used
for Pep-3 and described in the manufacturer’s guidelines.
Cyclin B1 protein levels were determined after 24h by
western blotting. For cellular localization experiments,
cells were grown on acid-treated glass coverslips to 60%
conﬂuence and then overlaid with preformed antisense/
peptide complexes. After 1h, cells were rinsed twice and
cellular localization of FITC-labeled HyPNA-pPNA
and PNA was monitored by ﬂuorescence microscopy on
living cells.
Cytotoxicity assay
The cytotoxicity side eﬀects of the diﬀerent HypNA-
pPNA/carrier complexes were determined with a MTT
assay after 24h. HUVEC and Jurkat T cell lines were
cultured for 24h prior incubation with diﬀerent HypNA-
pPNA/carrier preparations. In order to evaluate the
toxicity associated to antisense/carrier complexes, the
diﬀerent carriers were associated to the control mismatch
antisense Cyc-B1
mm HypNA-pPNA sequence. The speciﬁc
antisense response was then calculated as a ratio of cyclin
B1 to total protein and corrected for toxicity of the
complexes.
Mousetumour model
Athymic female nude mice (6–8 weeks of age) were
subcutaneously inoculated in the ﬂank with 1 10
6
PC3 cells in 100ml PBS. A week after tumour implant,
when tumour size reached  50–100mm
3, animals were
treated by intratumoral or intravenous injection, every
three days, with a solution of 0.1 or 0.2ml of diﬀerent
antisense HypNA-pPNA formulations. Mice received
either free HypNA-pPNA (50 or 100mg) or HypNA-
pPNA complexed (1, 5 and 10mg) to Pep-3 or Pep-2at a
20/1 molar ratio. Formulations containing 20% of
PEGylated-Pep-3 were obtained by forming a precomplex
HypNA-pPNA/Pep-3at molar ratio of 1/5 and then
increasing the ratio of antisense/carrier up to 1/20 with
PEG-Pep-3. The tumour diameter was measured in two
directions at regular intervals using a digital calliper and
volumes were calculated using the formula
length width height 0.52 (22). Curves show the
mean value of tumour size in a group of ﬁve animals
and no animal death nor any sign of toxicity were
observed. After 25 days, tumours were removed, and
cyclin B1 protein levels were evaluated by western
blotting. Experiments were performed according to
national regulations and approved by the local animal
experimentation ethical committee.
Characterization ofcomplex formation
Fluorescence titration experiments were performed as
previously described (16,23), on a PTI QuantaMaster
spectroﬂuorometer at 258C, using band-passes of 6 and
8nm for excitation and emission, respectively.
Tryptophan ﬂuorescence emission was recorded over a
range of 305–400nm, with an excitation wavelength of
295nm. A ﬁxed concentration of carrier-peptide (100nM)
was titrated with increasing concentrations of PNA and
HypNA-pPNA (between 0 and 500nM) at 258C in water.
Fitting of titration curves was accomplished using
a quadratic equation and Graﬁt Software (Erithacus
Software Ltd) as previously described (16,23). All results
correspond to the average of four separate experiments
with a standard deviation smaller than 10%. Mean
particle size distribution was determined with a Coulter
N4 Plus (Coulter-Beckman) at 258C for 3min per
measurement.
RESULTS AND DISCUSSIONS
Designand evaluation of peptidecarriers
The sequence of Pep-2 (K E T W F E T W F T E W S Q P
K K K R K V-Cya) previously described (19), was used as
a template for screening new peptide vectors for in vitro
and in vivo delivery of PNAs and analogues. A series of
mutations and deletions were performed in order to
identify the essential residues required to form stable
complexes with PNAs and analogues and to improve their
delivery into cells (Table 1). The impact of each residue
on Pep-2 eﬃcacy was evaluated by alanine scanning
throughout the sequence of Pep-2. Moreover, as aromatic
residues are required for both binding of the carrier to
PNAs and cellular uptake, the impact of the position
of the Trp and Phe residues in the N-terminal hydro-
phobic sequence was investigated. As we have previously
reported that the cysteamide group at the C-terminus
of peptide is required for its cellular uptake and
delivery eﬃcacy, all peptides were synthesized with a
cysteamide at their C-terminus and acetylated at their
N-terminus (17,18).
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form stable complexes with PNAs and HyPNA-pPNAs,
and improve the cellular uptake of ﬂuorescently labelled
HyPNA-pPNAs. The binding to PNAs or PNA analogues
was monitored by ﬂuorescence spectroscopy, using the
intrinsic ﬂuorescence of the Trp residues located in
the hydrophobic domain of the peptide as a sensor of
the interaction (Figure 1B). The potency of the peptides to
deliver ﬂuorescently labelled HyPNA-pPNAs into cul-
tured cells was monitored by ﬂuorescence microscopy on
living cells (Figure 1C). Typical experiments and data are
reported in Figure 1. Our results reveal that major
interactions between DNA mimics and the peptide carrier
are mediated by the hydrophobic domain of the peptide
and that tight binding of the carrier to PNA analogues,
with nanomolar aﬃnity, is a prerequisite for eﬃcient
delivery. However, results obtained with peptides Pep-20
and Pep-34 to Pep-39 (Table 1) indicate that this feature
alone is insuﬃcient and that the number of charges also
plays a critical role for eﬃcient cellular uptake. These
results enabled us to identify key residues required for
optimal carrier functions and to propose the following
rules for sequence optimization. Irrespective of the
sequence of the hydrophobic moiety of the peptide, a
minimum of four cationic residues is required within the
hydrophilic domain. The number of charged residues has
a major impact on the initial electrostatic interactions of
the peptide with the cell membrane components as already
reported for several cell-penetrating peptides (24–26). In
addition, three residues are critical for both delivery and
solubility of the peptide, the charged N-terminal Lys
1
residue, Thr
7 between the two Trp-Phe motifs and Pro
14 in
the linker motif that enables ﬂexibility between the
hydrophobic and the hydrophilic domains. The position
of the Trp-Phe tandem in the hydrophobic sequence is
equally critical for cell entry of the peptide carrier
associated with PNAs or PNA analogues. Structural
characterization of Pep-1 and Pep-2 has shown that the
N-terminal hydrophobic sequence of the peptide has the
tendency to adopt an alpha helical structure at high
concentration or in the presence of lipids (23). Projection
of the helical domain in Pep-2 reveals that all aromatic
residues create an interaction patch located on the same
side of the helix (Figure 2B). Based on our peptide screen,
it is clear that this helical organization should be taken
into account for optimization of peptide carriers, and
any modiﬁcations that even slightly aﬀect binding to
cargoes may have a dramatic impact on cellular uptake.
These results strengthen the notion that the helical
organization of Pep carriers is a determining factor for
their interaction with the cell membrane, thereby enabling
aromatic residues on this helix to interact with lipids and
Table 1. Evaluation of Pep-2-peptide derivatives
Peptides Sequences Binding
a Uptake
b
Pep-2 K E T W FETWFTEWSQPKKKRKV-Cya þþþ þþþ
Pep-20 A E T W FETWFTEWSQPKKKRKV-Cya þþþ  
Pep-21 K A T W FETWFTEWSQPKKKRKV-Cya þþþ þþþ
Pep-22 K E A W FETWFTEWSQPKKKRKV-Cya þþ þþ
Pep-23 K E T A FETWFTEWSQPKKKRKV-Cya   
Pep-24 K E T W A E T W FTEWSQPKKKRKV-Cya   
Pep-25 K E T W F A T W FTEWSQPKKKRKV-Cya þþ þþ
Pep-26 K E T W F E A W FTEWSQPKKKRKV-Cya þ 
Pep-27 K E T W FETAFTEWSQPKKKRKV-Cya   
Pep-28 K E T W FETWATEWSQPKKKRKV-Cya   
Pep-29 K E T W FETWFAEWSQPKKKRKV-Cya þþþ þþþ
Pep-30 K E T W FETWFTAWSQPKKKRKV-Cya þþþ þþþ
Pep-31 K E T W FETWFTEASQPKKKRKV-Cya þþþ þþ
Pep-32 K E T W FETWFTEWAQPKKKRKV-Cya þþþ þþþ
Pep-33 K E T W FETWFTEWSAPKKKRKV-Cya þþþ þþþ
Pep-34 K E T W FETWFTEWSQAKKKRKV-Cya þþ  
Pep-35 K E T W FETWFTEWSQPAKKRKV-Cya þþþ þ
Pep-36 K E T W FETWFTEWSQPKAKRKV-Cya þþþ þ
Pep-37 K E T W FETWFTEWSQPKKARKV-Cya þþþ þþ
Pep-38 K E T W FETWFTEWSQPKKKAKV-Cya þþþ þ
Pep-39 K E T W FETWFTEWSQPKKKRAV-Cya þþþ þ
Pep-40 K E T W FETWFTEWSQPKKKRKA-Cya þþþ þþþ
Pep-41 W F K ETETWFTEWSQPKKKRKV-Cya þþ  
Pep-42 K W F ETETWFTEWSQPKKKRKV-Cya þþþ þþ
Pep-42 K E W FTETWFTEWSQPKKKRKV-Cya þþþ þþ
Pep-43 K E T W FETWFTEWSQPKKKRKV-Cya þþþ þþþ
Pep-44 K ETEWFTWFTEWSQPKKKRKV-Cya þþ  
Pep-45 K ETETWFWFTEWSQPKKKRKV-Cya þþþ  
Pep-46 K ETETTWFWFEWSQPKKKRKV-Cya þþ þ
Pep-47 K ETETTEWFWFWSQPKKKRKV-Cya þ 
aBinding of peptide to PNA or HypNA-pPNA was monitored by ﬂuorescence spectroscopy, using the intrinsic ﬂuorescence of the Trp residues.
Data were ﬁtted as reported in Figure 1A and symbols þþþ, þþ, þ and   correspond to dissociation constant values respectively lower than
100nM, 500nM, 1mM and higher than 1mM.
bCellular uptake was determined using ﬂuorescently labelled PNA or HypNA-pPNA, as described in Figure 1B, symbols þþþ, þþ, þ
and   correspond to 480%, 50%, 510% and a lack of delivery eﬃciency, respectively.
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previously suggested (23).
Taking these rules into account, we designed a 15-
residue peptide; Pep-3 (ac-K W F E T W F T E W P K K
R K-Cya), that bears all residues required for eﬃcient
uptake of HyPNA-pPNAs and has a tendency to adopt a
helical structure within membranes. Pep-3 interacts with
PNAs and PNA analogues with a dissociation constant
of  10–20nM depending on the nature of the cargo
(Figure 1B). Saturation of Pep3/HyPNA-pPNA complex
formation occurs for a molar peptide/cargo ratio of
 20, which is in perfect agreement with our previous
ﬁnding for Pep-1 and derived peptides (17,23). As
reported in Figure 1C (panel 3 and 4), Pep-3 signiﬁ-
cantly facilitates cellular uptake of both PNAs and
HypNA-pPNAs. Determination of the size of these
particles by light scattering reveals that Pep-3 forms
stable particles with HyPNA-pPNAs (Kd¼15 2nM)
in the range of 0.092 0.01mm diameter, in contrast
to Pep-2 which exhibits a slightly lower aﬃnity for
PNAs (Kd¼37 8nM) and forms average size particles
of 0.34 0.1mm diameter within a more dispersed
population.
Pep-3 mediated delivery of antisense HypNA-pPNA in vitro
The potency of Pep-3 to deliver HypNA-pPNA in a
biologically relevant system was investigated using anti-
sense targeting cyclin B1. Cyclin B1 is a non-redundant
cyclin, and an essential component of ‘Mitosis Promoting
Factor’, which it forms together with its partner protein
kinase Cdk1 (27). Alteration in both expression and
activation of cyclin B1 have been shown to be associated
to numerous cancers, thus an antisense approach control-
ling cyclin B1 levels has been proposed as an anti-
proliferative strategy of choice (28,29). We have designed
three diﬀerent antisense sequences against the open ready
frame of the cyclin B1 gene: Cyc-B1a, Cyc-B1b and
Cyc-B1c (Figure 3A). These antisense HypNA-pPNA
were complexed with Pep-3at a molar ratio of 1/20, and
their impact on cyclin B1 protein levels was evaluated on
Hela cells. As reported in Figure 3B, a concentration of 50
nM of antisense Cyc-B1a or Cyc-B1b HypNA-pPNA
altered cyclin B1 protein levels by 85 and 63%,
respectively, in a speciﬁc fashion by comparison to the
antisense luciferase control that has no eﬀect on cyclin B1
levels. In contrast, antisense Cyc-B1c HypNA-pPNA
yielded a limited biological response (less than 10%),
which may be due to the poor accessibility of the target
sequence. Dose response analysis of the three antisense
revealed that, when complexed to Pep-3, antisense Cyc-
B1a and Cyc-B1b eﬃciently downregulate cyclin B1
protein levels in HeLa cells with an IC50 of 12 3 and
of 31 5nM, respectively (Figure 3B and C). However,
only Cyc-B1a is able to reduce cyclin B1 levels by more
than 90%. In contrast, no eﬀect on cyclin B1 protein levels
was observed in the presence of a control HypNA-pPNA
sequence harbouring two mutations complexed with
Pep-3. Given its high eﬃciency, antisense Cyc-B1a
HypNA-pPNA was used throughout the rest of the study.
Pep-3mediated delivery ofantisense HypNA-pPNA into
primary and suspension cell lines
Numerous delivery methods have been described as highly
potent on commonly used adherent cell lines; in contrast,
only few are able to eﬃciently transfect primary and
suspension cell lines. In particular, toxicity is a major issue
when considering the development of delivery systems for
primary and suspension cell lines. Hence, prior to
characterizing the speciﬁcity of antisense eﬀect, we ﬁrst
evaluated the toxicity of diﬀerent delivery systems
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Figure 2. Sequence alignment and structural properties of Pep-2 and Pep-3. (A) sequence alignment of the diﬀerent peptide carriers. Residues
involved in cargo binding and cellular uptake are in red and blue, respectively. Structural model of Pep-2 and Pep-3. The structure of Pep-3 was
elaborated based on the structure of Pep-1, previously determined by NMR
23, using Discover/Insight II package (MSI Inc., San Diego, USA) and
Delano Scientiﬁc LLC Pymol software (San Carlo, USA).
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plexed with the mismatch antisense CycB1
mm HypNA-
pPNA on HUVEC and Jurkat T cells. On both cell lines,
no signiﬁcant toxicity (less than 10%), was observed with
Pep-3 and Pep-2, up to a 2mM concentration of antisense.
In contrast, cell viability was reduced by  52% (HUVEC)
and 70% (Jurkat T) in the presence of Lipofectamine
using the same antisense concentration. Subsequently,
the eﬃciency of cyc-B1a HypNA-pPNA/Pep-3 was
evaluated on diﬀerent cell lines, including HUVEC,
Jurkat T, MCF 7 and PC3 cell lines. Typical western
blot analysis demonstrated that irrespective of the cell line,
a 100 nM concentration of antisense HypNA-pPNA
complexed with Pep-3, was suﬃcient for robust silencing
of cyclin B1at the protein level, ranging from 70% for
Jurkat cells to 95% for HUVEC cells (Figure 4A).
The potential of Pep-3 to deliver Cyc-B1a HypNA-
pPNA into cell lines which are quite challenging
to transfect, such as primary HUVECs and Jurkat was
then investigated in comparison with other delivery
methods including the cell penetrating peptides (Pep-2,
MPG) or a cationic lipid formulation (Lipofectamine). As
reported in Figure 4B, the four delivery methods used
enabled delivery of cyc-B1a HypNA-pPNA into HUVEC
cells, however the speciﬁc antisense response obtained
with Pep-3 (IC50 of 7.2 2nM) was respectively
3-, 15- and 70-fold, greater than that obtained with
Pep-2 (IC50:2 1  5nM), Lipofectamine (IC50:
120 10nM) and MPG (IC504500nM). Remarkably,
Pep-3-mediated delivery was the only strategy providing a
signiﬁcant and speciﬁc antisense response on Jurkat
T cells, with 70–80% downregulation of cyclin B1 (IC50:
24 5nM). In contrast, no signiﬁcant biological response
was obtained with either MPG or Lipofectamine and only
a moderate antisense response was obtained with Pep-2
(IC5041.5mM). The relatively low eﬃciency of MPG
on both cell lines is probably associated to the low
stability of the complex. Indeed MPG has been shown to
be more appropriate for delivery of nucleic acids and
its hydrophobic domain does not harbour any Trp
residues, which are essential to stabilize the interaction
with PNA or HypNA-pPNA (16,18). Taken together,
these results demonstrate that sequence optimization
of Pep-2 to Pep-3 constitutes a major improvement over
Pep-2 carrier whose eﬃciency is limited in suspension
cell lines.
Pep-3mediateddeliveryofantisenseHypNA-pPNAtargeting
cyclin B1in vivo
In vivo, bioavailability of DNA mimics constitutes one of
the major limitations in therapeutics (1–4). The potential
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Pep-3at a molar ratio 1:20at 378C for one hour, then overlaid onto cultured cells. Cyclin B1 protein levels were analysed by western blotting after
30h. Control experiments performed with 2mM of CycB1
mm (mm) HypNA-pPNA containing two mutations. (D) Dose response analysis
of increasing concentrations (5, 10, 25, 50 and 100nM) of HypNA-pPNA Cyc-B1a, Cyc-B1b and Cyc-B1c. HypNA-pPNAs were incubated
with Pep-3at a molar ratio 1:20at 378C for one hour, then overlaid onto cultured cells. Cyclin B1 protein levels were analysed by western blotting
after 30h.
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vivo was evaluated on human prostate carcinoma cell
(PC3) xenografted mice. This mouse tumour model was
used to test systemic administration of Pep-3/antisense on
the growth inhibition of established subcutaneous
tumours. Formulations of Pep-3/HypNA-pPNA com-
plexes at a 20/1 molar ratio (Figure 5A), were adminis-
tered intravenously or directly into the tumour every three
days, and changes in tumour size were monitored over a
course of two weeks following injection. As a control, we
show that administration of 50mg (intratumorally) and
100mg (intravenously) of naked HyPNA-pPNA or of
Pep-3 do not produce any signiﬁcant eﬀect on tumour
growth. As reported in Figure 5B, intratumoral injection
of Pep-3/HyPNA-pPNA potently inhibits tumour growth
in a concentration-dependent manner, with 50% inhibi-
tion for 1mg and more than 92% for 5mg of antisense
HyPNA-pPNA. In contrast, intravenous administration
of Pep-3/HyPNA-pPNA (10mg of antisense) only reduces
tumour growth by  20%, whilst of Pep-2/HyPNA-pPNA
complexes have no eﬀect on tumour growth, supporting
the idea that in vivo eﬃciency is directly associated with
the size and stability of Pep-based ‘nanoparticles’.
PEGylation improves Pep-3efficiency in vivo
PEGylation plays a key role in drug delivery and has been
reported to enhance in vivo potency and stability of
numerous therapeutic molecules (30). As such to improve
the stability of Pep-3/HypNA-pPNA particles in vivo, the
sequence of Pep-3 was modiﬁed by the attachment of a
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Figure 4. Pep-3-mediated delivery of an antisense cyclin B1 HypNA-pPNA in primary and suspension cell lines. (A) Pep-3-mediated delivery of
antisense cyclin B1 HypNA-pPNA was evaluated on diﬀerent cell lines. Here, 100nM of antisense HypNA-pPNA was complexed with Pep-3at a
molar ratio 1:20, then evaluated on Jurkat T (lane 3), HUVEC (lane 4), PC3 (lane 5) and MCF7 (lane 6). Also, 100 nM of antisense HypNA-pPNA
was complexed with Pep-2at the same ratio and evaluated on Jurkat T (lane 2). The level of endogenous cyclin B1 in untreated cells is reported in
lane 1. (B/C) Comparison of Pep-3 strategy to other delivery methods. Increasing concentrations from 5 nM to 1mM of HypNA-pPNA Cyc-B1a
were associated with Pep-3, Pep-2 or MPG at a molar ratio 1:20 or with Lipofectamine, then overlaid onto cultured HUVEC (panel B) and Jurkat
(panel C) cells. Cyclin B1 protein levels were analysed by western blotting after 30h and antisense eﬀect was normalized. (D/E): Toxicity of the
diﬀerent delivery methods: HUVEC (panel E) and Jurkat (panel F) cells, were incubated with increasing concentrations of Cyc-B1
mm HypNA-pPNA
complexed with Pep-3, Pep-2, MPG and Lipofectamine. Cell viability was evaluated by MTT assay after 24h.
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have established a protocol to obtain formulations
containing PEGylated-Pep-3, in which the HyPNA-
pPNA is ﬁrst associated to unPEGylated Pep-3at a
molar ratio of 1/5, which is then adjusted to 1/20 using
diﬀerent concentrations of PEG-Pep-3 (Figure 5A). We
found that formulations containing up to 15% of
PEGylated-Pep-3 exhibit the same eﬃciency and ability
to reduce levels of cyclin B1 on cultured cells. Xenografted
mice were intravenously treated with 10mg of antisense
HypNA-pPNA complexed with Pep-3/PEG-Pep-3 (80/20).
As shown in Figure 5C, the PEGylated formulation
signiﬁcantly improves delivery and stability of the com-
plex, and eﬃciently inhibits tumour growth by more than
90%, which is 4–5-fold more eﬃcient than unPEGylated
Pep-3. Moreover, we demonstrated that the eﬀect on
tumour growth is sequence speciﬁc as an antisense
HyPNA-pPNA bearing two mutations complexed to
PEG-Pep-3 was unable to inhibit tumour growth. As
reported in Figure 5D, the eﬀect on tumour growth can be
correlated to a decrease in the levels of cyclin B1 protein
by  60% in animals treated with Pep-3/HyPNA-pPNA
(5mg/intratumorally) or with HypNA-pPNA/Pep-3/PEG-
Pep-3 (10mg/intravenously), which is consistent with the in
vitro antisense impact and suggests a speciﬁc eﬀect
associated with the cyclin B1 antisense.
CONCLUSIONS
Improved design and chemistry of charged and uncharged
DNA mimics has yielded highly stable molecules, which
exhibit high aﬃnity for their target and low toxicity due to
their eﬃciency (1–5). However, the challenge to their
in vivo administration remains in their therapeutic
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intratumoral administration. Mice inoculated with PC3 tumour cells were left untreated (red circles) or treated every three days by intratumoral
injection of 50mg of naked HypNA-pPNA, (blue circles) or 1 (green circles) and 5mg (fuchsia circles) of antisense associated with Pep-3. (C) Tumour
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control to normalize protein levels.
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inapplicable in vivo, given their poor cellular uptake and
their lack of rational targeting (3–6). In the present study,
we have elaborated a strategy combining a non-covalent
peptide-based delivery system and a charged PNA-like
DNA mimic that is likely to have potent implications
in therapeutics. HypNA-pPNA DNA mimics have already
been used successfully both in vitro and in vivo
(19,20,31,32) and oﬀer several advantages due to their
tight interaction with target DNA as well as their high
solubility (21,32). Cell-penetrating peptides are most
promising tools for delivery of therapeutic molecules
(8,9) and the recent reconsideration of their cellular
uptake mechanism has provided new perspectives for
their in vivo application (25,26). Here, we demonstrate that
key parameters need to be taken into account in the design
of a non covalent peptide-based delivery strategy, includ-
ing the secondary structure of the carrier, the presence of a
critical number of charged and aromatic residues, as well
as the size and the stability of the carrier/cargo particles.
Using a rational approach we have designed a new
peptide, Pep-3, which forms ‘nanoparticles’ with charged
and uncharged PNAs and improves their delivery into a
large panel of cell lines as well as into an animal model.
These results reveal a correlation between biological
eﬃciency, carrier/cargo aﬃnity, complex stability, particle
size and homogeneity. Pep-3/antisense HypNA-pPNA
particles targeting the cell cycle regulatory protein cyclin
B1 were successfully applied in vivo through intratumoral
and intravenous administration and were found to inhibit
tumour growth as eﬃciently as proven siRNA molecules.
In vivo delivery of HypNA-pPNA is a potent strategy for
several therapies. Here we demonstrate not only that a
peptide-based nanoparticle system eﬃciently delivers such
PNA mimics into living cells and animal tumour models,
but also that it can be improved by PEGylation of the
carrier, which stabilizes the complexes. This study shows
that such a modiﬁcation signiﬁcantly improves Pep-3 for
in vivo systemic administration, allowing us to reduce the
dose required to induce a speciﬁc and robust biological
response, thereby limiting non-speciﬁc cytotoxic eﬀects
described upon treatment with high concentrations of
PNAs. Together, these data reveal that Pep-3 constitutes
an excellent candidate for in vivo delivery of charged PNA
and DNA mimics. Moreover, Pep-3 is a potent delivery
approach, which is far more appropriate for suspension
and primary cell lines than other currently used methods,
and which exhibits far less toxicity than other delivery
systems.
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